Clinical Trials Sponsored by Taiho Pharmaceuticals

Total 19783 results

Taisho Pharmaceutical Co., Ltd.

Completed

A Study Of The Effect Of PF-04802540 On Sleep Measures

Healthy

United States
Taiko Pharmaceutical Co., Ltd.

Unknown

Test of a Preventive Effect of a Deodorant Device Against Respiratory Infections (Cleverin)

Respiratory Infection

Japan
SRI International
Taiho Pharmaceutical Co., Ltd.

Completed

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

Breast Cancer

United States
Peking University
Taiho Pharmaceutical Co., Ltd.

Unknown

A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery

Gastric Cancer

China
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

Healthy Adult Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Late Phase II Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Insomnia Disorder

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy of SFPP in Knee Osteoarthritis

Osteoarthritis Knee Pain

Indonesia
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Healthy Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

Healthy Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Study of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.

Patients With Mild Obstructive Sleep Apnea Hypopnea

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole)

Healthy Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects

Healthy Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Healthy Male Subjects

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

Narcolepsy

Japan, Korea, Republic of
Taisho Pharmaceutical Co., Ltd.

Completed

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

Chronic Kidney Disease

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers

Healthy

Singapore
Taisho Pharmaceutical Co., Ltd.

Completed

Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

Schizophrenia

United States
Taisho Pharmaceutical R&D Inc.

Completed

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

Healthy Volunteers

United States
Taisho Pharmaceutical R&D Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

Major Depressive Disorder

United States
Taisho Pharmaceutical R&D Inc.

Completed

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

Healthy Volunteers

United States
Taisho Pharmaceutical R&D Inc.

Completed

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

Atopic Dermatitis

United States
Taisho Pharmaceutical R&D Inc.

Completed

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Healthy Volunteers

United States
Taisho Pharmaceutical R&D Inc.

Completed

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

Healthy Volunteers

United States
Taisho Pharmaceutical R&D Inc.

Completed

Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects

Healthy Volunteers

United States
National Cancer Centre, Singapore
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NSCLC

Singapore
University of Wisconsin, Madison
Taiho Pharmaceutical Co., Ltd.

Terminated

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Neoplasms | Cancer | Neuroendocrine Tumors | Tumors

United States
Taiho Pharmaceutical Co., Ltd.
Yakult Honsha Co., LTD

Completed

Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer (SOLAR)

Gastric Cancer

Japan, Korea, Republic of
Taiho Pharmaceutical Co., Ltd.
Daiichi Sankyo Co., Ltd.

Completed

Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Colorectal Cancer

Japan
University of California, Irvine
Taiho Pharmaceutical Co., Ltd.

Completed

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | GastroEsophageal Cancer

United States
Sun Yat-sen University
Taiho Pharmaceutical Co., Ltd.

Completed

Study of S-1 Plus LV for Advanced Gastric Cancer

Gastric Cancer

China
Taiho Pharmaceutical Co., Ltd.
Yakult Honsha Co., LTD

Completed

Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer

Colorectal Cancer

Japan
M.D. Anderson Cancer Center
Taiho Pharmaceutical Co., Ltd.

Completed

Phase I Study of TAS-106 in Combo With Carboplatin

Cancer | Solid Tumors

United States
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
Taiho Oncology, Inc.

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4)

Advanced Cholangiocarcinoma | FGFR2 Fusions | Gene Rearrangement

United States, Korea, Republic of, Spain, Japan, Portugal, Italy, China, Argentina, Brazil, Poland, Australia
Taiho Oncology, Inc.

Recruiting

A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Advanced or Metastatic Solid Tumors

United States, France
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Taiho Oncology, Inc.

Terminated

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

United States, United Kingdom, Austria, France
Taiho Oncology, Inc.

Completed

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Advanced or Metastatic Non-small Cell Lung Cancer

United States, France, Poland, Spain, Italy, Japan
Taiho Oncology, Inc.

Completed

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Refractory Metastatic Colorectal Cancer

United States
Taiho Oncology, Inc.

Completed

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Advanced Solid Tumors

United States, Czechia, Serbia
Taiho Oncology, Inc.

Completed

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

Advanced Solid Tumors

United States
Taiho Oncology, Inc.

Terminated

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Taiho Oncology, Inc.

Terminated

An Investigation of TAS-119 Monotherapy

Advanced Solid Tumors

Italy, Spain, United States, Netherlands, United Kingdom
Taiho Oncology, Inc.

Completed

A Trial of TAS-114 in Combination With S-1

Advanced Solid Tumors

France, Belgium, Italy, Switzerland
Taiho Oncology, Inc.

Completed

A Study of TAS-116 in Patients With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Italy

Clinical Trials Sponsored by Taiho Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations